Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATAD2 | Q6PL18 | 2/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | LGMN | Q99538 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | ALPL | P05186 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL88218 | 0.77 | ALDH1A1 (0.47) | ATAD2KDM4EALDH1A1GLAKMT2A | |
| SCHEMBL22521815 | 0.76 | LGMN (0.38) | ATAD2LGMN | |
| Water SCHEMBL3902406 | 0.75 | ALDH1A1 (0.46) | ATAD2KDM4EALDH1A1GLAKMT2A | |
| Hydrochloric Acid SCHEMBL6316692 | 0.75 | ALDH1A1 (0.46) | ATAD2KDM4EALDH1A1GLAKMT2A | |
| SCHEMBL13024710 | 0.74 | ATAD2 (0.39) | ATAD2KDM4EALDH1A1LGMNPOLB | |
| SCHEMBL13024384 | 0.74 | ADORA2A (0.41) | ATAD2KDM4EALDH1A1LGMNPOLB | |
| SCHEMBL8175084 | 0.72 | ADORA2A (0.48) | ALDH1A1LMNAADORA2APDE4AADORA2B | |
| SCHEMBL12169061 | 0.70 | ADORA2A (0.36) | ATAD2KDM4EALDH1A1LGMNPOLB | |
| SCHEMBL1689679 | 0.70 | LGMN (0.36) | ATAD2KDM4EALDH1A1LGMNKMT2A | |
| SCHEMBL15384321 | 0.70 | ALDH1A1 (0.46) | ATAD2KDM4EALDH1A1GLAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023150592-A2 | N3-SUBSTITUTED URACIL COMPOUNDS AS TRPA1 INHIBITORS | D.E. SHAW RESEARCH, LLC (US) | 2023-08-10 | — | — | WO | disclosed |
| WO-2020205646-A2 | SMALL MOLECULE PARG INHIBITORS AND METHODS OF USE THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-10-08 | — | — | WO | disclosed |
| EP-2708538-B1 | Process for preparing fused pyrimidine-dione derivatives, useful as as TRPA1 modulators | GLENMARK PHARMACEUTICALS SA (CH) | 2015-08-12 | — | — | EP | disclosed |
| US-9000159-B2 | Fused pyrimidine-dione derivatives as TRPA1 modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2015-04-07 | — | — | US | disclosed |
| US-20140128603-A1 | FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2014-05-08 | — | — | US | disclosed |
| EP-2708538-A1 | Process for preparing fused pyrimidine-dione derivatives, useful as as TRPA1 modulators | Glenmark Pharmaceuticals S.A. (CH) | 2014-03-19 | — | — | EP | disclosed |
| EP-2411393-B1 | FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS SA (CH) | 2014-01-22 | — | — | EP | disclosed |
| US-8623880-B2 | Fused pyrimidine-dione derivatives as TRPA1 modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2014-01-07 | — | — | US | disclosed |
| US-20120041004-A1 | FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPAI MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-02-16 | — | — | US | disclosed |
| EP-2411393-A1 | FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPA1 MODULATORS | Glenmark Pharmaceuticals S.A. (CH) | 2012-02-01 | — | — | EP | disclosed |
| US-8022122-B2 | Derivatives of pyrimidines as flame retardants | BASF SE (DE) | 2011-09-20 | — | — | US | disclosed |
| WO-2010109287-A1 | FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2010-09-30 | — | — | WO | disclosed |
| US-20090131565-A1 | Derivatives of Pyrimidines as Flame Retardants | BASF SE (DE) | 2009-05-21 | — | — | US | disclosed |
| US-5185341-A | Antiamnestic, antihypoxic compounds | ARZNEIMITTELWERK DRESDEN GMBH (DE) | 1993-02-09 | — | — | US | disclosed |
| EP-0484660-A1 | Novel 5-(Phenoxyalcanoylamino)-uraciles, methodes for preparing them and their use as medicaments | ARZNEIMITTELWERK DRESDEN GmbH (DE) | 1992-05-13 | — | — | EP | disclosed |
| US-4608383-A | Cardioactive pyrazole and imidazole aryloxypropanolamines | BOEHRINGER MANNHEIM GMBH (DE) | 1986-08-26 | — | — | US | disclosed |
| EP-0042593-B1 | ARYLOXY-PROPANOL AMINES, PROCESS FOR THEIR PREPARATION AND MEDICINES CONTAINING THESE COMPOUNDS | Roche Diagnostics GmbH (DE) | 1985-04-03 | — | — | EP | disclosed |
| US-4438128-A | ADRENERGIC BLOCKERS | BOEHRINGER MANNHEIM GMBH (DE) | 1984-03-20 | — | — | US | disclosed |
| EP-0042593-A1 | Aryloxy-propanol amines, process for their preparation and medicines containing these compounds | Roche Diagnostics GmbH (DE) | 1981-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128603-A1 | FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPA1 MODULATORS | TRPA1, TRPV1, TRPV2 | ATAD2 1145/4885BCHE 4357/4885PTGS2 214/4885 |
| US-20120041004-A1 | FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPAI MODULATORS | TRPA1, TRPV1, TRPC3 | ATAD2 1743/4885BCHE 4562/4885PTGS2 389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.